Angiogenesis inhibitors in advanced cancer; many current clinical trials are yielding promising results;Angiogeneshämmare vid avancerad cancer: Många påbörjade kliniska prövningar visar lovande resultat

Lakartidningen

Volumn , Issue 20, 1998, Pages 2349-2354

  Christofferson, Rolf ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032513630     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 1997; 3: 443-6.
3. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1487-93.
4. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clinical Cancer Research 1997; 3: 1501-6.
5. DeVore RF, Hellerquist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA et al. Phase I study of the antineovascularization drug CM101. Clinical Cancer Research 1997; 3: 365-72.
6. Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ et al. Phase I trial of micronized formulation of carboxyaminotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997; 15: 1985-93.
7. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
8. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
9. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
10. O'Reilly MS, Holmgren L, Chen CC, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
11. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
12. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-6.
13. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-50.
14. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
15. Ferrara N, Carver-Moore K, Chen H, Dowd M, O'Shea KS, Powell-Braxton L et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
16. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP et al. FIk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-5.
17. Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN Jr, McCrimmon D et al. Squalamine: An aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A 1993; 80: 1354-8.
18. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.